DLB

Dolby Laboratories, Inc.
$58.84
+0.48 (+0.82%)
Mkt Cap 5.51B
Volume 616,965
52W Range 48.26-69.95
Sector Technology
Beta 0.78
EPS (TTM) 2.38 USD
P/E Ratio 24.72
Revenue (TTM) 1.35B USD
Rev Growth (5Y) +3.0%
EPS Growth (5Y) +2.9%
AlphaVal · Fair Value
What we estimate one share is worth
$56.33
Overvalued weak signal
4.5% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B
Stable Earnings Power
69.4 / 100 composite
Steady, predictable earnings power — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 1.35B 1.27B 1.30B 1.25B 1.28B 1.16B 1.24B 1.05B 1.08B 1.03B 970.64M 960.18M
Net Income 255.02M 261.82M 200.66M 184.09M 310.23M 231.36M 255.15M 41.75M 201.80M 185.86M 181.39M 206.10M
EPS 2.66 2.74 2.00 1.84 3.07 2.30 2.51 1.18 1.98 1.85 1.75 2.02
Free Cash Flow 430.26M 297.25M 336.74M 259.12M 393.30M 274.86M 214.14M 266.85M 272.93M 138.28M 114.44M 248.23M
FCF / Share 4.49 3.11 3.52 2.59 3.89 2.73 2.11 2.58 2.68 1.37 1.12 2.43
Operating CF 472.20M 327.25M 367.08M 318.58M 447.75M 343.85M 327.67M 352.20M 377.79M 360.06M 309.38M 361.55M
Total Assets 3.23B 3.13B 2.99B 2.70B 3.12B 2.94B 2.82B 2.87B 2.54B 2.32B 2.13B 1.98B
Total Debt 38.88M 46.99M 50.65M 50.94M 72.12M 81.14M 0 0 0 0 0 0
Cash & Equiv 701.89M 577.75M 817.97M 628.37M 1.23B 1.08B 805.59M 925.25M 634.37M 519.76M 534.86M 570.61M
Book Value 2.62B 2.48B 2.36B 2.25B 2.60B 2.43B 2.31B 2.19B 2.14B 1.97B 1.81B 1.71B
Return on Equity 0.10 0.11 0.09 0.08 0.12 0.10 0.11 0.02 0.09 0.09 0.10 0.12
DLB News
Dolby Laboratories Announces Conference Call and Webcast for Q4 Fiscal 2026 Financial Results
Oct 12, 2026 04:30 AM · prnewswire.com
Dolby Laboratories (NYSE:DLB) & Palo Alto Networks (NASDAQ:PANW) Financial Contrast
Oct 12, 2026 02:44 AM · defenseworld.net
Analyzing Dolby Laboratories (NYSE:DLB) & Aware (NASDAQ:AWRE)
Oct 07, 2026 04:17 AM · defenseworld.net
Dolby Laboratories: Weak Growth, But The Valuation Is Too Cheap
Oct 04, 2026 10:04 PM · seekingalpha.com
Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB
Sep 29, 2026 03:30 AM · globenewswire.com
Dolby Expands Meta Partnership With Atmos and Vision Across Devices
Sep 24, 2026 06:01 AM · zacks.com
Financial Analysis: Zscaler (NASDAQ:ZS) vs. Dolby Laboratories (NYSE:DLB)
Sep 24, 2026 12:15 AM · defenseworld.net
Dolby and Meta Expand Dolby Atmos and Dolby Vision Across Meta's Ecosystem
Sep 23, 2026 05:00 PM · gurufocus.com
Dolby and Meta Expand Dolby Atmos and Dolby Vision Across Meta's Ecosystem
Sep 23, 2026 04:00 PM · prnewswire.com
Dolby Laboratories, Inc. Grants Inducement Equity Awards Under Its 2026 Inducement Stock Plan
Sep 15, 2026 03:00 PM · prnewswire.com